comparemela.com
  1. Home
  2. Live Updates
  3. Hang Quach - Breaking News

Latest Breaking News On - Hang quach - Page 1 : comparemela.com

Practice-changing study on bone marrow cancer therapy

Practice-changing study on bone marrow cancer therapy
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Michele cavoMeral beksacAurore perrotCyrille hulinMeletiosa dimopoulosHermann einseleMario boccadoroSilvia mangiacavalliXavier leleuPieter sonneveldEuropean myeloma networkJanssen researchUniversity hospitalNational tumour centreMedical clinicEuropean myeloma

Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma

- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) of Australia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in triple class refractory R/R MM. - This inclusion by the Pharmaceutical Benefits Scheme (PBS) for the treatment of patients with R/R MM.

United statesSouth koreaHong kongPeter qianAsia pacificMark hendersonDan mellorKaryopharm therapeutics incHong kong stock exchangeTherapeutic goods administrationPrnewswire antengene corporation limitedCompany annualAntengene corporation limitedPharmaceutical benefits schemeCorporation limitedHang quach

Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma

Belamaf plus lenalidomide-dexamethasone achieved encouraging responses

United statesMike bassettUniversity of melbourneSociety of hematologic oncologySagar lonialWinship cancer instituteEmory universityHematologic oncologyHang quach

Approved Treatment for Relapsed and Refractory Multiple Myeloma

In Australia around 2,400 people are diagnosed each year with multiple myeloma (MM), and around 20,000 patients are living with MM at any given time. 

United statesSouth koreaAndrew spencerThomas karalisJay meiAsia pacificAntengene corporationAustralian government department of healthTherapeutic goods administrationCorporation limitedAustralian government departmentHang quachProfessor andrew spencerAlfred hospitalMyeloma australia

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. -.

Hong kongUnited statesSouth koreaAndrew spencerThomas karalisJay meiAsia pacificPeter qianCompany annualAntengene corporationDrug administrationAustralian government department of healthHong kong stock exchangePrnewswire antengene corporation limitedAntengene corporation limitedTherapeutic goods administration

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.